Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Workiva Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Workiva Inc trades at $72.22 (market cap $3.95B). The key difference: Workiva Inc is far larger — about 4.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Workiva Inc is more actively traded (612,757 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Workiva Inc for 20 Days on average.
| MRVI | WK | |
|---|---|---|
Market Cap | $972.90M | $3.95B |
Volume | 4,325,710 | 612,757 |
Sector | Health | Technology |
52-Week High | $9.00 | $93.31 |
52-Week Low | $2.83 | $44.31 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $1.08B | $3.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
WK trades at $72.50, down 0.74% on the day, with strong technical momentum showing bullish moving averages and support at $72. The company demonstrates robust revenue growth, reaching $966M in 2026 with net income turning positive at $47M, while consistently beating earnings expectations. Recent product innovations in AI and regulatory technology highlight ongoing business development.
The outlook remains positive with 89% analyst buy ratings and an $86 price target, though elevated valuation multiples and execution risks in competitive markets warrant caution. Upside potential exists if earnings growth continues, but investors should monitor margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
